Shares of Pieris Pharmaceuticals Inc. (PIRS) Exceed 52-Week High

IBN Spotlights
Friday, September 24, 2021 at 3:50pm UTC

Shares of Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) traded at a new 52-week high today of $6.15. Approximately 29.7 million shares have changed hands today, as compared to an average 30-day volume of 1.6 million shares.

Over the past year, Pieris Pharmaceuticals Inc. has traded in a range of $1.70 to $6.15 and is now at $5.79, 241% above that low.

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm functions through the region of the United States.

Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) defies analysts with a current price ($5.79) 23.7% above its average consensus price target of $4.42.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer